Xencor, Inc.
http://www.xencor.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xencor, Inc.
EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody
If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.
Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement
ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies